Compare INDB & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INDB | ADPT |
|---|---|---|
| Founded | 1907 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.5B |
| IPO Year | 1994 | 2019 |
| Metric | INDB | ADPT |
|---|---|---|
| Price | $79.26 | $24.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $93.43 | $29.81 |
| AVG Volume (30 Days) | 416.7K | ★ 2.3M |
| Earning Date | 10-15-2026 | 11-04-2026 |
| Dividend Yield | ★ 3.32% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 3.33 | N/A |
| Revenue | N/A | ★ $276,976,000.00 |
| Revenue This Year | $20.49 | $5.94 |
| Revenue Next Year | $4.88 | $22.42 |
| P/E Ratio | $23.15 | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $65.45 | $12.00 |
| 52 Week High | $87.50 | $30.74 |
| Indicator | INDB | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 52.65 | 37.90 |
| Support Level | $79.61 | $23.73 |
| Resistance Level | $80.52 | $26.51 |
| Average True Range (ATR) | 1.60 | 1.44 |
| MACD | 0.10 | -0.49 |
| Stochastic Oscillator | 89.53 | 0.43 |
Independent Bank Corp is a bank holding company and the sole shareholder of its bank, the Rockland Trust Company. Rockland is a community-oriented commercial bank. The bank provides a variety of banking, investment and financial services, operating with various retail branches, as well as a network of commercial and residential lending centers and investment management offices majorly in Eastern Massachusetts, Worcester County, and Rhode Island. The bank's loan portfolio constitutes the bulk of the bank's total assets. Its borrowers consist mostly of small to medium-size businesses and consumers, majority of which are made to its market area in eastern Massachusetts and Rhode Island. The bank's loan portfolio is predominantly in commercial loans.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.